{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T13:20:57Z","timestamp":1788096057868,"version":"build-2803163510"},"reference-count":89,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T00:00:00Z","timestamp":1579737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Huntington\u2019s disease (HD) is a fatal neurodegenerative disease caused by a CAG expansion mutation in the huntingtin gene. As a result, intranuclear inclusions of mutant huntingtin protein are formed, which damage striatal medium spiny neurons (MSNs). A review of Positron Emission Tomography (PET) studies relating to HD was performed, including clinical and preclinical data. PET is a powerful tool for visualisation of the HD pathology by non-invasive imaging of specific radiopharmaceuticals, which provide a detailed molecular snapshot of complex mechanistic pathways within the brain. Nowadays, radiochemists are equipped with an impressive arsenal of radioligands to accurately recognise particular receptors of interest. These include key biomarkers of HD: adenosine, cannabinoid, dopaminergic and glutamateric receptors, microglial activation, phosphodiesterase 10 A and synaptic vesicle proteins. This review aims to provide a radiochemical picture of the recent developments in the field of HD PET, with significant attention devoted to radiosynthetic routes towards the tracers relevant to this disease.<\/jats:p>","DOI":"10.3390\/molecules25030482","type":"journal-article","created":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T11:41:57Z","timestamp":1580125317000},"page":"482","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Huntington\u2019s Disease: A Review of the Known PET Imaging Biomarkers and Targeting Radiotracers"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3530-2845","authenticated-orcid":false,"given":"Klaudia","family":"Cybulska","sequence":"first","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Geert Grooteplein-Zuid 10, 6525 EZ Nijmegen, The Netherlands"},{"name":"Radboud Translational Medicine B.V., Radboud University Medical Center, Geert Grooteplein 21 (route 142), 6525 EZ Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8190-4447","authenticated-orcid":false,"given":"Lars","family":"Perk","sequence":"additional","affiliation":[{"name":"Radboud Translational Medicine B.V., Radboud University Medical Center, Geert Grooteplein 21 (route 142), 6525 EZ Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Booij","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Geert Grooteplein-Zuid 10, 6525 EZ Nijmegen, The Netherlands"},{"name":"Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Laverman","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Geert Grooteplein-Zuid 10, 6525 EZ Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8495-4703","authenticated-orcid":false,"given":"Mark","family":"Rijpkema","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Geert Grooteplein-Zuid 10, 6525 EZ Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,1,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(14)61010-2","article-title":"Slowing of neurodegeneration in Parkinson\u2019s disease and Huntington\u2019s disease: Future therapeutic perspectives","volume":"384","author":"Schapira","year":"2014","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3389\/fneur.2017.00011","article-title":"Molecular Imaging Markers to Track Huntington\u2019s Disease Pathology","volume":"8","author":"Wilson","year":"2017","journal-title":"Front. Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s00259-016-3324-6","article-title":"Current status of PET imaging in Huntington\u2019s disease","volume":"43","author":"Pagano","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11910-018-0890-y","article-title":"Novel Imaging Biomarkers for Huntington\u2019s Disease and Other Hereditary Choreas","volume":"18","author":"Fazio","year":"2018","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3233\/JHD-150171","article-title":"PET Imaging in Huntington\u2019s Disease","volume":"4","author":"Roussakis","year":"2015","journal-title":"J. Huntingtons. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.cell.2019.06.036","article-title":"CAG Repeat Not Polyglutamine Length Determines Timing of Huntington\u2019s Disease Onset","volume":"178","author":"Lee","year":"2019","journal-title":"Cell"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.3174\/ajnr.A3772","article-title":"Genetics of Huntington Disease","volume":"35","author":"Mahalingam","year":"2014","journal-title":"Am. J. Neuroradiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.arr.2018.11.006","article-title":"Targeting the proteostasis network in Huntington\u2019s disease","volume":"49","author":"Soares","year":"2019","journal-title":"Ageing Res. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1534\/genetics.116.195578","article-title":"Genetic contributors to intergenerational CAG repeat instability in Huntington\u2019s disease knock-in mice","volume":"205","author":"Neto","year":"2017","journal-title":"Genetics"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.1073\/pnas.96.8.4604","article-title":"Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: Implications for Huntington\u2019s disease pathology","volume":"96","author":"Scherzinger","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.pediatrneurol.2019.07.003","article-title":"Positron Emission Tomography in Pediatric Neurodegenerative Disorders","volume":"100","author":"Chugani","year":"2019","journal-title":"Pediatr. Neurol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s13311-012-0112-2","article-title":"Huntington\u2019s Disease and the Striatal Medium Spiny Neuron: Cell-Autonomous and Non-Cell-Autonomous Mechanisms of Disease","volume":"9","author":"Ehrlich","year":"2012","journal-title":"Neurotherapeutics"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"6975841","DOI":"10.1155\/2017\/6975841","article-title":"In Vivo PET Imaging of Adenosine 2A Receptors in Neuroinflammatory and Neurodegenerative Disease","volume":"2017","author":"Vuorimaa","year":"2017","journal-title":"Contrast Media Mol. Imaging"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1089\/caff.2018.0006","article-title":"The Role of Adenosine Tone and Adenosine Receptors in Huntington\u2019s Disease","volume":"8","author":"Blum","year":"2018","journal-title":"J. Caffeine Adenosine Res."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Morigaki, R., and Goto, S. (2017). Striatal Vulnerability in Huntington\u2019s Disease: Neuroprotection Versus Neurotoxicity. Brain Sci., 7.","DOI":"10.3390\/brainsci7060063"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.bbamem.2010.12.001","article-title":"Adenosine receptors and brain diseases: Neuroprotection and neurodegeneration","volume":"1808","author":"Gomes","year":"2011","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S1474-4422(03)00411-3","article-title":"Adenosine receptors and Huntington\u2019s disease: implications for pathogenesis and therapeutics","volume":"2","author":"Blum","year":"2003","journal-title":"Lancet Neurol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5150","DOI":"10.1021\/jm020905i","article-title":"Synthesis and Evaluation of No-Carrier-Added 8-Cyclopentyl-3-(3-[18F]fluoropropyl)-1-propylxanthine ([18F]CPFPX): A Potent and Selective A1-Adenosine Receptor Antagonist for in Vivo Imaging","volume":"45","author":"Holschbach","year":"2002","journal-title":"J. Med. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"v","DOI":"10.1016\/j.nucmedbio.2017.09.004","article-title":"Consensus nomenclature rules for radiopharmaceutical chemistry\u2014Setting the record straight","volume":"55","author":"Coenen","year":"2017","journal-title":"Nucl. Med. Biol."},{"key":"ref_20","first-page":"1682","article-title":"Evaluation of 18F-CPFPX, a Novel Adenosine A1 Receptor Ligand: In Vitro Autoradiography and High-Resolution Small Animal PET","volume":"44","author":"Bauer","year":"2003","journal-title":"J. Nucl. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1007\/s00259-014-2724-8","article-title":"Cross sectional PET study of cerebral adenosine A1 receptors in premanifest and manifest Huntington\u2019s disease","volume":"41","author":"Matusch","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_22","first-page":"345","article-title":"11C-Labeled KF18446: A Potential Central Nervous System Adenosine A2a Receptor Ligand","volume":"41","author":"Ishiwata","year":"2000","journal-title":"J. Nucl. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/BF02988643","article-title":"Adenosine A2A receptor imaging with [11C]KF18446 PET in the rat brain after quinolinic acid lesion: Comparison with the dopamine receptor imaging","volume":"16","author":"Ishiwata","year":"2002","journal-title":"Ann. Nucl. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3389\/fncel.2016.00294","article-title":"Cannabinoid Receptors in the Central Nervous System: Their Signaling and Roles in Disease","volume":"10","author":"Kendall","year":"2017","journal-title":"Front. Cell. Neurosci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/0306-4522(93)90352-G","article-title":"Loss of cannabinoid receptors in the substantia nigra in Huntington\u2019s disease","volume":"56","author":"Glass","year":"1993","journal-title":"Neuroscience"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0306-4522(00)00008-7","article-title":"The pattern of neurodegeneration in Huntington\u2019s disease: a comparative study of cannabinoid, dopamine, adenosine and GABAA receptor alterations in the human basal ganglia in Huntington\u2019s disease","volume":"97","author":"Glass","year":"2000","journal-title":"Neuroscience"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.2967\/jnumed.110.077156","article-title":"Widespread Decrease of Type 1 Cannabinoid Receptor Availability in Huntington Disease In Vivo","volume":"51","author":"Casteels","year":"2010","journal-title":"J. Nucl. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/jlcr.3219","article-title":"Automated one-step radiosynthesis of the CB1 receptor imaging agent [18F]MK-9470","volume":"57","author":"Thomae","year":"2014","journal-title":"J. Label. Compd. Radiopharm."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"41432","DOI":"10.1038\/srep41432","article-title":"Striatal Neurons Expressing D1 and D2 Receptors are Morphologically Distinct and Differently Affected by Dopamine Denervation in Mice","volume":"7","author":"Gagnon","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1527-3458.2001.tb00207.x","article-title":"SCH 23390: The First Selective Dopamine D1-Like Receptor Antagonist","volume":"7","author":"Bourne","year":"2006","journal-title":"CNS Drug Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0014-2999(85)90459-5","article-title":"Positron tomography of a radio-brominated analog of the D1\/DA1 antagonist, SCH 23390","volume":"108","author":"Friedman","year":"1985","journal-title":"Eur. J. Pharmacol."},{"key":"ref_32","first-page":"47","article-title":"Evaluation of positron-emitting SCH 23390 analogs as tracers for CNS dopamine D1 receptors","volume":"16","author":"Dejesus","year":"1989","journal-title":"Nucl. Med. Biol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13550-018-0416-2","article-title":"[11C]SCH23390 binding to the D1-dopamine receptor in the human brain\u2014A comparison of manual and automated methods for image analysis","volume":"8","author":"Stenkrona","year":"2018","journal-title":"EJNMMI Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0883-2889(87)90022-0","article-title":"Synthesis of [11C]SCH 23390 for dopamine D1 receptor studies","volume":"38","author":"DeJesus","year":"1987","journal-title":"Int. J. Rad. Appl. Instr. A"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/0883-2889(86)90044-4","article-title":"Preparation of 11C-labelled SCH 23390 for the in vivo study of dopamine D-1 receptors using positron emission tomography","volume":"37","author":"Halldin","year":"1986","journal-title":"Appl. Radiat. Isot."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/BF02191583","article-title":"Dopamine D1 receptor number\u2014A sensitive PET marker for early brain degeneration in Huntington\u2019s disease","volume":"243","author":"Sedvall","year":"1994","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1093\/brain\/122.12.2353","article-title":"Huntington\u2019s disease progression: PET and clinical observations","volume":"122","author":"Andrews","year":"1999","journal-title":"Brain"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2967\/jnumed.116.180497","article-title":"Longitudinal Small-Animal PET Imaging of the zQ175 Mouse Model of Huntington Disease Shows In Vivo Changes of Molecular Targets in the Striatum and Cerebral Cortex","volume":"58","author":"Tari","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_39","first-page":"2061","article-title":"Carbon-11-NNC 112: A Radioligand for PET Examination of Striatal and Neocortical D1-Dopamine Receptors","volume":"39","author":"Halldin","year":"1998","journal-title":"J. Nucl. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1002\/hbm.21134","article-title":"Extrastriatal dopamine D2 receptor binding in Huntington\u2019s disease","volume":"32","author":"Esmaeilzadeh","year":"2011","journal-title":"Hum. Brain Mapp."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0020-708X(85)90083-3","article-title":"Preparation of 11C-labelled raclopride, a new potent dopamine receptor antagonist: Preliminary PET studies of cerebral dopamine receptors in the monkey","volume":"36","author":"Ehrin","year":"1985","journal-title":"Int. J. Appl. Radiat. Isot."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1002\/(SICI)1099-1344(199912)42:12<1183::AID-JLCR274>3.0.CO;2-Z","article-title":"Precursor synthesis and radiolabelling of the dopamine D2 receptor ligand [11C]raclopride from [11C]methyl triflate","volume":"42","author":"Langer","year":"1999","journal-title":"J. Label. Compd. Radiopharm."},{"key":"ref_43","first-page":"2501","article-title":"Evaluation of base-free 11C-Raclopride synthesis with various solvents","volume":"56","author":"Lee","year":"2015","journal-title":"J. Nucl. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1139\/cjc-2012-0331","article-title":"Continuous-flow synthesis of [11C]raclopride, a positron emission tomography radiotracer, on a microfluidic chip","volume":"91","author":"Haroun","year":"2013","journal-title":"Can. J. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/MNM.0b013e32834b45a3","article-title":"Fully automated and reproducible radiosynthesis of high specific activity [11C]raclopride and [11C]Pittsburgh compound-B using the combination of two commercial synthesizers","volume":"32","author":"Llop","year":"2011","journal-title":"Nucl. Med. Commun."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/ana.410430216","article-title":"[11C]Raclopride-PET studies of the Huntington\u2019s disease rate of progression: Relevance of the trinucleotide repeat length","volume":"43","author":"Antonini","year":"1998","journal-title":"Ann. Neurol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.nbd.2009.10.015","article-title":"Cortical dopamine dysfunction in symptomatic and premanifest Huntington\u2019s disease gene carriers","volume":"37","author":"Pavese","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"180165","DOI":"10.1098\/rsob.180165","article-title":"Insights into GABAAergic system alteration in Huntington\u2019s disease","volume":"8","author":"Hsu","year":"2018","journal-title":"Open Biol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/cns.12826","article-title":"Alteration of GABAergic neurotransmission in Huntington\u2019s disease","volume":"24","author":"Garret","year":"2018","journal-title":"CNS Neurosci. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/1531-8249(200005)47:5<644::AID-ANA13>3.0.CO;2-C","article-title":"Benzodiazepine receptor binding in Huntington\u2019s disease: [11C]Flumazenil uptake measured using positron emission tomography","volume":"47","author":"Leenders","year":"2000","journal-title":"Ann. Neurol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jlcr.1152","article-title":"Rapid preparation of [11C]flumazenil: captive solvent synthesis combined with purification by analytical sized columns","volume":"50","author":"Cleij","year":"2007","journal-title":"J. Label. Compd. Radiopharm."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"eaan6387","DOI":"10.1126\/scisignal.aan6387","article-title":"mGluR5 antagonism increases autophagy and prevents disease progression in the zQ175 mouse model of Huntington\u2019s disease","volume":"10","author":"Hamilton","year":"2017","journal-title":"Sci. Signal."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1517\/14728222.2014.948419","article-title":"Metabotropic glutamate receptor 5 as a potential therapeutic target in Huntington\u2019s disease","volume":"18","author":"Ribeiro","year":"2014","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1523\/JNEUROSCI.4974-09.2010","article-title":"Metabotropic Glutamate Receptor-Mediated Cell Signaling Pathways Are Altered in a Mouse Model of Huntington\u2019s Disease","volume":"30","author":"Ribeiro","year":"2010","journal-title":"J. Neurosci."},{"key":"ref_55","first-page":"698","article-title":"Radiosynthesis and Preclinical Evaluation of 11C-ABP688 as a Probe for Imaging the Metabotropic Glutamate Receptor Subtype 5","volume":"47","author":"Ametamey","year":"2006","journal-title":"J. Nucl. Med."},{"key":"ref_56","first-page":"247","article-title":"Human PET Studies of Metabotropic Glutamate Receptor Subtype 5 with 11C-ABP688","volume":"48","author":"Ametamey","year":"2007","journal-title":"J. Nucl. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s00259-010-1723-7","article-title":"In vivo positron emission tomography imaging with [11C]ABP688: binding variability and specificity for the metabotropic glutamate receptor subtype 5 in baboons","volume":"38","author":"DeLorenzo","year":"2011","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.2967\/jnumed.118.210658","article-title":"Longitudinal Characterization of mGluR5 Using 11C-ABP688 PET Imaging in the Q175 Mouse Model of Huntington Disease","volume":"59","author":"Bertoglio","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/hbm.21008","article-title":"Microglial activation in regions related to cognitive function predicts disease onset in Huntington\u2019s disease: A multimodal imaging study","volume":"32","author":"Politis","year":"2011","journal-title":"Hum. Brain Mapp."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Dupont, A.C., Largeau, B., Santiago Ribeiro, M., Guilloteau, D., Tronel, C., and Arlicot, N. (2017). Translocator Protein-18 kDa (TSPO) Positron Emission Tomography (PET) Imaging and Its Clinical Impact in Neurodegenerative Diseases. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18040785"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/s41593-018-0242-x","article-title":"Microglia in neurodegeneration","volume":"21","author":"Hickman","year":"2018","journal-title":"Nat. Neurosci."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s12149-008-0136-1","article-title":"In vivo imaging of microglial activation using a peripheral benzodiazepine receptor ligand: [11C]PK-11195 and animal PET following ethanol injury in rat striatum","volume":"22","author":"Toyama","year":"2008","journal-title":"Ann. Nucl. Med."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Alves, V.H., Abrunhosa, A.J., and Castelo-Branco, M. (2013, January 20\u201323). Optimisation of synthesis, purification and reformulation of (R)-[N-Methyl-11C]PK11195 for in vivo PET imaging studies. Proceedings of the 2013 IEEE 3rd Portuguese Meeting in Bioengineering (ENBENG), Braga, Portugal.","DOI":"10.1109\/ENBENG.2013.6518428"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1093\/brain\/awm044","article-title":"Microglial activation in presymptomatic Huntington\u2019s disease gene carriers","volume":"130","author":"Tai","year":"2007","journal-title":"Brain"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/hmg\/ddy202","article-title":"TSPO-PET imaging using [18F]PBR06 is a potential translatable biomarker for treatment response in Huntington\u2019s disease: preclinical evidence with the p75NTR ligand LM11A-31","volume":"27","author":"Simmons","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2967\/jnumed.109.068064","article-title":"Biodistribution and Radiation Dosimetry in Humans of a New PET Ligand, 18F-PBR06, to Image Translocator Protein (18 kDa)","volume":"51","author":"Fujimura","year":"2010","journal-title":"J. Nucl. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/syn.20394","article-title":"Kinetic evaluation in nonhuman primates of two new PET ligands for peripheral benzodiazepine receptors in brain","volume":"61","author":"Imaizumi","year":"2007","journal-title":"Synapse"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.steroids.2011.06.012","article-title":"Synthesis of [11C]PBR06 and [18F]PBR06 as agents for positron emission tomographic (PET) imaging of the translocator protein (TSPO)","volume":"76","author":"Wang","year":"2011","journal-title":"Steroids"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1021\/jm8011855","article-title":"Single-Step High-Yield Radiosynthesis and Evaluation of a Sensitive 18F-Labeled Ligand for Imaging Brain Peripheral Benzodiazepine Receptors with PET","volume":"52","author":"Briard","year":"2009","journal-title":"J. Med. Chem."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/jnc.13855","article-title":"[18F]JNJ42259152 binding to phosphodiesterase 10A, a key regulator of medium spiny neuron excitability, is altered in the presence of cyclic AMP","volume":"139","author":"Ooms","year":"2016","journal-title":"J. Neurochem."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.neuroscience.2003.11.009","article-title":"Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington\u2019s disease transgenic mice prior to the onset of motor symptoms","volume":"123","author":"Hebb","year":"2004","journal-title":"Neuroscience"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.neulet.2018.08.006","article-title":"PET Radioligands for imaging of the PDE10A in human: Current status","volume":"691","author":"Boscutti","year":"2019","journal-title":"Neurosci. Lett."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1021\/jm200536d","article-title":"Synthesis, In Vivo Occupancy, and Radiolabeling of Potent Phosphodiesterase Subtype-10 Inhibitors as Candidates for Positron Emission Tomography Imaging","volume":"54","author":"Iturrino","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.2967\/jnumed.112.118679","article-title":"Quantification of 18F-JNJ-42259152, a Novel Phosphodiesterase 10A PET Tracer: Kinetic Modeling and Test-Retest Study in Human Brain","volume":"54","author":"Ahmad","year":"2013","journal-title":"J. Nucl. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s00259-012-2270-1","article-title":"Human biodistribution and dosimetry of 18F-JNJ42259152, a radioligand for phosphodiesterase 10A imaging","volume":"40","author":"Ahmad","year":"2013","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1212\/WNL.0000000000000037","article-title":"PET imaging shows loss of striatal PDE10A in patients with Huntington disease","volume":"82","author":"Ahmad","year":"2014","journal-title":"Neurology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.2967\/jnumed.113.122895","article-title":"In Vivo Assessment and Dosimetry of 2 Novel PDE10A PET Radiotracers in Humans: 18F-MNI-659 and 18F-MNI-654","volume":"55","author":"Barret","year":"2014","journal-title":"J. Nucl. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/jamaneurol.2014.1954","article-title":"The Phosphodiesterase 10 Positron Emission Tomography Tracer, [18F]MNI-659, as a Novel Biomarker for Early Huntington Disease","volume":"71","author":"Russell","year":"2014","journal-title":"JAMA Neurol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1212\/WNL.0000000000002391","article-title":"Change in PDE10 across early Huntington disease assessed by [18F]MNI-659 and PET imaging","volume":"86","author":"Russell","year":"2016","journal-title":"Neurology"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2967\/jnumed.113.131409","article-title":"Phosphodiesterase 10A PET Radioligand Development Program: From Pig to Human","volume":"55","author":"Plisson","year":"2014","journal-title":"J. Nucl. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1093\/brain\/awv214","article-title":"Altered PDE10A expression detectable early before symptomatic onset in Huntington\u2019s disease","volume":"138","author":"Niccolini","year":"2015","journal-title":"Brain"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.mcn.2019.02.001","article-title":"Synaptic vesicle protein 2A as a potential biomarker in synaptopathies","volume":"97","author":"Heurling","year":"2019","journal-title":"Mol. Cell. Neurosci."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1124\/mol.111.076687","article-title":"The Synaptic Vesicle Glycoprotein 2A Ligand Levetiracetam Inhibits Presynaptic Ca2+ Channels through an Intracellular Pathway","volume":"82","author":"Vogl","year":"2012","journal-title":"Mol. Pharmacol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ddtec.2017.11.003","article-title":"Discovery and development of SV2A PET tracers: Potential for imaging synaptic density and clinical applications","volume":"25","author":"Mercier","year":"2017","journal-title":"Drug Discov. Today Technol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/cmdc.201300482","article-title":"Discovery of Heterocyclic Nonacetamide Synaptic Vesicle Protein 2A (SV2A) Ligands with Single-Digit Nanomolar Potency: Opening Avenues towards the First SV2A Positron Emission Tomography (PET) Ligands","volume":"9","author":"Mercier","year":"2014","journal-title":"ChemMedChem"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.trci.2017.08.004","article-title":"Measuring brain synaptic vesicle protein 2A with positron emission tomography and [18F]UCB-H","volume":"3","author":"Bahri","year":"2017","journal-title":"Alzheimer\u2019s Dement. Transl. Res. Clin. Interv."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2967\/jnumed.115.168179","article-title":"Synthesis and Preclinical Evaluation of 11C-UCB-J as a PET Tracer for Imaging the Synaptic Vesicle Glycoprotein 2A in the Brain","volume":"57","author":"Nabulsi","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_88","first-page":"1624","article-title":"Improved synthesis of [11C]UCB-J for PET imaging of synaptic density","volume":"60","author":"DiFilippo","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Bertoglio, D., Verhaeghe, J., Miranda, A., Kertesz, I., Cybulska, K., Korat, \u0160., Wyffels, L., Stroobants, S., Mrzljak, L., and Dominguez, C. (2019). Validation and noninvasive kinetic modeling of [11C]UCB-J PET imaging in mice. J. Cereb. Blood Flow Metab.","DOI":"10.1177\/0271678X19864081"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/3\/482\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:08:24Z","timestamp":1760364504000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/3\/482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,23]]},"references-count":89,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,2]]}},"alternative-id":["molecules25030482"],"URL":"https:\/\/doi.org\/10.3390\/molecules25030482","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,23]]}}}